Favorable Outcomes for Patients with Co-morbidities or Concomitant Medications Treated with U2: A Retrospective Analysis of UNITY-CLL Phase 3 Trial By admin / 12/13/2021
A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): a Minimal Residual Disease (MRD)-driven, Time-limited Approach By admin / 12/12/2021
Efficacy and Safety of Umbralisib and Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) By admin / 12/12/2021
The Combination of Umbralisib Plus Ublituximab is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global UNITY-NHL Trial By admin / 12/11/2021
The Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor TG-1701 as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-cell Malignancies By admin / 12/11/2021
Integrated Safety Analysis of Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor, in Relapsed/Refractory Lymphoid Malignancies By admin / 09/21/2021
A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) By admin / 09/19/2021
Phase I/II Study of Umbralisib (TGR-1202), Ublituximab (TG-1101), and Pembrolizumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Richter’s Transformation: 5-Year Follow-up By admin / 09/18/2021
Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 UNITY-CLL Study By admin / 09/18/2021
Phase I/II Study of Umbralisib (TGR-1202), Ublituximab (TG-1101), and Pembrolizumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Richter’s Transformation: 5-Year Follow-up By admin / 09/18/2021
